Shots: Novartis to receive $20M (€17.9M) up front, regulatory and commercial milestones plus royalties on sales. Pharming to get exclusive rights to develop and commercialize Novartis’ CDZ173 (leniolisib). Additionally, Pharming […]readmore
Tags : CDZ173